Please use this identifier to cite or link to this item:
標題: The association of anti-parvovirus B19-VP1 unique region antibodies with antiphospholipid antibodies in patients with antiphospholipid syndrome
作者: Chen, D.Y.
Tzang, B.S.
Chen, Y.M.
Lan, J.L.
Tsai, C.C.
Hsu, T.C.
關鍵字: Human parvovirus B19 (B19);VP1 unique region protein (VP1u);Antiphospholid antibody (aPL);Antiphospholipid syndrome (APS);Systemic;lupus erythematosus (SLE);systemic-lupus-erythematosus;minor capsid protein;b19 infection;vp1;unique;phospholipase a(2);linear epitopes;disease;induction;cofactor;classification
Project: Clinica Chimica Acta
期刊/報告no:: Clinica Chimica Acta, Volume 411, Issue 15-16, Page(s) 1084-1089.
Background: Human parvovirus B19 (B19) infection has been identified as a trigger of antiphospholipid syndrome (APS). However, the precise role of B19-VP1 unique region (VP1u) in patients with antiphospholipid syndrome remains unclear. Methods: IgM and IgG against B19-VP, and serum levels of antibodies directed against cardiolipin (CL), beta2-glycoprotein-I (beta 2GPI) and phospholipid (PhL) were determined using ELISA in 45 APS patients. Humoral responses of anti-B19-VP1u were assessed by Western blot and 819 DNA was detected by nested PCR. Absorption experiments were performed using B19-VP1u protein to determine the binding specificity of antiphospholipid antibodies (aPL). Results: One and 18 of 45 APS patients had detectable levels of anti-B19-VP IgM and anti-B19-VP IgG, indicating recent and past infection respectively. All serum samples from APS patients with diagnostic pattern DNA(-)/IgM(-)/IgG(+) had anti-B19-VP1u activity. APS patients with anti-B19-VP1u antibody had a 4-fold increased risk for recurrent vascular thrombosis compared with those without anti-B19-VP1u antibody. The binding inhibition of CL,beta 2GPI, and PhL by absorption with B19-VP1u ranged from 31.4% to 91.1%, 0.8% to 59.8% and 20.2% to 72.1% respectively. Significantly higher inhibition to beta 2GPI by B19-VP1u absorption was observed in APS patients with anti-B19-VP1u antibody than in those without anti-B19-VP1u antibody. Conclusions: We show a close association of B19 infection with aPL production and suggest B19-VP1u may be of pathogenetic importance in some patients with APS. (C) 2010 Elsevier B.V. All rights reserved.
ISSN: 0009-8981
DOI: 10.1016/j.cca.2010.04.004
Appears in Collections:期刊論文

Show full item record

Google ScholarTM




Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.